Antimalarials in the treatment of schistosomiasis

Current Pharmaceutical Design

Volumn 18, Issue 24, 2012, Pages 3531-3538

  Keiser, Jennifer ^a,b   Utzinger, Jürg ^a,b  

^a SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Antimalarial drugs; Artemisinins; Malaria; Mefloquine; Schistosomiasis; Synthetic trioxolanes

Indexed keywords

ANTIMALARIAL AGENT; ANTIMONY TARTRATE; ANTISCHISTOSOMAL AGENT; ARTEMETHER; ARTEROLANE; ARTESUNATE; ARTESUNATE PLUS MEFLOQUINE; FURAPROMIDUM; MEFLOQUINE; METAKELFIN; OXAMNIQUINE; OZ 288; OZ 418; PA 1259; PRAZIQUANTEL; Q 27877; UNCLASSIFIED DRUG;

DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MALARIA; MONOTHERAPY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SCHISTOSOMA HEMATOBIUM; SCHISTOSOMA JAPONICUM; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; SINGLE DRUG DOSE; TROPICAL DISEASE;

EID: 84861206771     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212801327293     Document Type: Review

References (92)

1. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Ehrlich Sachs S, Sachs JD, Savioli L. Control of neglected tropical diseases. N Engl J Med 2007; 357: 1018-27.
2. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, metaanalysis, and estimates of people at risk. Lancet Infect Dis 2006; 6: 411-25.
3. Utzinger J, Raso G, Brooker S, de Savigny D, Tanner M, Ørnbjerg N, Singer BH, N'Goran EK. Schistosomiasis and neglected tropical diseases: towards integrated and sustainable control and a word of caution. Parasitology 2009; 136: 1859-74.
4. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368: 1106-18.
5. Gray DJ, Ross AG, Li YS, McManus DP. Diagnosis and management of schistosomiasis. BMJ 2011; 342: d2651.
6. Hürlimann E, Schur N, Boutsika K, Stensgaard AS, Laserna de Himpsl M, Ziegelbauer K, Laizer N, Camenzind L, Di Pasquale A, Ekpo UF, Simoonga C, Mushinge G, Saarnak CFL, Utzinger J, Kristensen TK, Vounatsou P. Toward an open-access global database for mapping, control, and surveillance of neglected tropical diseases. PLoS Negl Trop Dis 2011; 5: e1404.
7. Schur N, Hürlimann E, Stensgaard AS, Chimfwembe K, Mushinge G, Simoonga C, Kabatereine NB, Kristensen TK, Utzinger J, Vounatsou P. Spatially explicit Schistosoma infection risk in eastern Africa using Bayesian geostatistical modelling. Acta Trop (in press; doi:10.1016/j.actatropica.2011.10.006).
8. van der Werf MJ, de Vlas SJ, Brooker S, Looman CWN, Nagelkerke NJD, Habbema JDF, Engels D. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 2003; 86: 125-39.
9. WHO. Prevention and control of schistosomiasis and soil- transmitted helminthiasis: report of a WHO expert committee. WHO Tech Rep Ser 2002; 912: 1-57.
10. WHO. The World Health Report 2004: changing history, World Health Organization: Geneva 2004.
11. King CH, Dickman K, Tisch DJ. Reassessment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. Lancet 2005; 365: 1561-9.
12. King CH, Dangerfield-Cha M. The unacknowledged impact of chronic schistosomiasis. Chronic Illn 2008; 4: 65-79.
13. Murray CJL, Lopez AD, Black R, Mathers CD, Shibuya K, Ezzati M, Salomon JA, Michaud CM, Walker N, Vos T. Global burden of disease 2005: call for collaborators. Lancet 2007; 370: 109-10.
14. Christopherson JB. The successful use of antimony in bilharziosis administered as intravenous injections of ammonium tartaratum (tartar emetic). Lancet 1918; 192: 325-7.
15. Utzinger J, Keiser J. Schistosomiasis and soil-transmitted helminthiasis: common drugs for treatment and control. Expert Opin Pharmacother 2004; 5: 263-85.
16. Katz N, Coelho PM. Clinical therapy of schistosomiasis mansoni: the Brazilian contribution. Acta Trop 2008; 108: 72-8.
17. Xiao SH, Keiser J, Cheng MG, Tanner M, Utzinger J. Research and development of antischistosomal drugs in the People's Republic of China: a 60-year review. Adv Parasitol 2010; 73: 231-95.
18. Davis A, Biles JE, Ulrich AM. Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium. Bull World Health Organ 1979; 57: 773-9.
19. WHO. The control of schistosomiasis: report of a WHO expert committee. WHO Tech Rep Ser 1985; 728: 1-113.
20. Doenhoff MJ, Cioli D, Utzinger J. Praziquantel: mechanisms of action, resistance and new derivatives for schistosomiasis. Curr Opin Infect Dis 2008; 21: 659-67.
21. Meyer T, Sekljic H, Fuchs S, Bothe H, Schollmeyer D, Miculka C. Taste, a new incentive to switch to (R)-praziquantel in schistosomiasis treatment. PLoS Negl Trop Dis 2009; 3: e357.
22. Sabah AA, Fletcher C, Webbe G, Doenhoff MJ. Schistosoma mansoni: chemotherapy of infections of different ages. Exp Parasitol 1986; 61: 294-303.
23. Fenwick A, Savioli L, Engels D, Bergquist NR, Todd MH. Drugs for the control of parasitic diseases: current status and development in schistosomiasis. Trends Parasitol 2003; 19: 509-15.
24. Link H, Stohler HR. 3-Arylhydantoine, eine Substanzklasse mit schistosomizider Wirkung. Eur J Med Chem 1984; 19: 261-5.
25. Keiser J, Utzinger J. Advances in the discovery and development of novel trematocidal drugs. Expert Opin Drug Discov 2007; 2 (Suppl 1): 9-23.
26. Policy Cures. G-Finder 2010 global funding of innovation for neglected diseases. Neglected disease research and development: is the global financial crisis changing R&D? Sydney, London 2011.
27. Hotez PJ, Molyneux DH, Fenwick A, Ottesen E, Ehrlich Sachs S, Sachs JD. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 2006; 3: e102.
28. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-57.
29. Hotez PJ, Molyneux DH, Fenwick A, Savioli L, Takeuchi T. A global fund to fight neglected tropical diseases: is the G8 Hokkaido Toyako 2008 summit ready? PLoS Negl Trop Dis 2008; 2: e220.
30. Utzinger J, N'Goran EK, Caffrey CR, Keiser J. From innovation to application: social-ecological context, diagnostics, drugs and integrated control of schistosomiasis. Acta Trop 2011; 120 (Suppl 1): S121-37.
31. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Hall BF, Levine MM, Mendis K, Newman RD, Plowe CV, Rodriguez MH, Sinden R, Slutsker L, Tanner M. A research agenda to underpin malaria eradication. PLoS Med 2011; 8: e1000406.
32. Caffrey CR, Williams DL, Todd MJ, Nelson DL, Keiser J, Utzinger J. In: Selzer PM, Ed. Antiparasitic and Antibacterial Drug Discovery. Wiley-Blackwell: Weinheim, Chemotherapeutic development strategies for schistosomiasis, 2009, pp. 301-21.
33. Caffrey CR, Secor WE. Schistosomiasis: from drug deployment to drug development. Curr Opin Infect Dis 2011; 24: 410-7.
34. Cioli D. Praziquantel: is there real resistance and are there alternatives? Curr Opin Infect Dis 2000; 13: 659-63.
35. Gryseels B, Mbaye A, de Vlas SJ, Stelma FF, Guissé F, Van Lieshout L, Faye D, Diop M, Ly A, Tchuem-Tchuenté LA, Engels D, Polman K. Are poor responses to praziquantel for the treatment of Schistosoma mansoni infections in Senegal due to resistance? An overview of the evidence. Trop Med Int Health 2001; 6: 864-73.
36. Melman SD, Steinauer ML, Cunningham C, Kubatko LS, Mwangi IN, Wynn NB, Mutuku MW, Karanja DM, Colley DG, Black CL, Secor WE, Mkoji GM, Loker ES. Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. PLoS Negl Trop Dis 2009; 3: e504.
37. Alonso D, Munoz J, Gascon J, Valls ME, Corachan M. Failure of standard treatment with praziquantel in two returned travelers with Schistosoma haematobium infection. Am J Trop Med Hyg 2006; 74: 342-4.
38. Hagan P, Appleton CC, Coles GC, Kusel JR, Tchuem-Tchuenté LA. Schistosomiasis control: keep taking the tablets. Trends Parasitol 2004; 20: 92-7.
39. Leathwick DM, Miller CM, Atkinson DS, Haack NA, Waghorn TS, Oliver AM. Managing anthelmintic resistance: untreated adult ewes as a source of unselected parasites, and their role in reducing parasite populations. N Z Vet J 2008; 56: 184-95.
40. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol 2009; 7: 864-74.
41. Mehta SR, Das S. Management of malaria: recent trends. J Commun Dis 2006; 38: 130-8.
42. Chong CR, Sullivan DJ, Jr. New uses for old drugs. Nature 2007; 448: 645-6.
43. Swinney DC, Anthony J. How were new medicines discovered? Nat Rev Drug Discov 2011; 10: 507-19.
44. White NJ. Qinghaosu (artemisinin): the price of success. Science 2008; 320: 330-4.
45. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, Kokwaro G, Ouma J, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruebush TK, 2nd, Danis M, Greenwood BM, Anderson RM, Olliaro P. Averting a malaria disaster. Lancet 1999; 353: 1965-7.
46. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin- based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev 2009; CD007483.
47. O'Brien C, Henrich PP, Passi N, Fidock DA. Recent clinical and molecular insights into emerging artemisinin resistance in Plasmodium falciparum. Curr Opin Infect Dis 2011; 24: 570-7.
48. Xiao SH, Booth M, Tanner M. The prophylactic effects of artemether against Schistosoma japonicum infections. Parasitol Today 2000; 16: 122-6.
49. Utzinger J, Xiao SH, Keiser J, Chen MG, Zheng J, Tanner M. Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites. Curr Med Chem 2001; 8: 1841-60.
50. Utzinger J, Xiao SH, Tanner M, Keiser J. Artemisinins for schistosomiasis and beyond. Curr Opin Investig Drugs 2007; 8: 105-16.
51. Liu R, Dong HF, Guo Y, Zhao QP, Jiang MS. Efficacy of praziquantel and artemisinin derivatives for the treatment and prevention of human schistosomiasis: a systematic review and meta- analysis. Parasit Vectors 2011; 4: 201.
52. Quinhaosu Antimalarial Coordinating Research Group. Antimalaria studies on qinghaosu. Chin Med J 1979; 92: 811-6.
53. Chen DJ, Fu LF, Shao PP, Wu FZ, Fan CZ, Shu H, Ren CX, Sheng XL. Experimental studies on antischistosomal activity of qinghaosu. Chin Med J 1980; 60: 422-5.
54. Le W, You J, Yang Y, Mei J, Guo H, Yang H, Zang C. Studies on the efficacy of artemether in experimental schistosomiasis. Acta Pharmaceut Sin 1982; 17: 187-93.
55. Le WJ, You JQ, Mei JY. Chemotherapeutic effect of artesunate in experimental schistosomiasis. Acta Pharmaceut Sin 1983; 18: 619-21.
56. Xiao SH, Catto BA. In vitro and in vivo studies of the effect of artemether on Schistosoma mansoni. Antimicrob Agents Chemother 1989; 33: 1557-62.
57. Xiao SH, Utzinger J, Chollet J, Endriss Y, N'Goran EK, Tanner M. Effect of artemether against Schistosoma haematobium in experimentally infected hamsters. Int J Parasitol 2000; 30: 1001-6.
58. Krishna S, Bustamante L, Haynes RK, Staines HM. Artemisinins: their growing importance in medicine. Trends Pharmacol Sci 2008; 29: 520-7.
59. Haynes RK, Chan WC, Wong HN, Li KY, Wu WK, Fan KM, Sung HH, Williams ID, Prosperi D, Melato S, Coghi P, Monti D. Facile oxidation of leucomethylene blue and dihydroflavins by artemisinins: relationship with flavoenzyme function and antimalarial mechanism of action. ChemMedChem 2010; 5: 1282-99.
60. Klonis N, Crespo-Ortiz MP, Bottova I, Abu-Bakar N, Kenny S, Rosenthal PJ, Tilley L. Artemisinin activity against Plasmodium falciparum requires hemoglobin uptake and digestion. Proc Natl Acad Sci USA 2011; 108: 11405-10.
61. Ding XC, Beck HP, Raso G. Plasmodium sensitivity to artemisinins: magic bullets hit elusive targets. Trends Parasitol 2011; 27: 73-81.
62. Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Xiao SH, Tanner M. Oral artemether for prevention of Schistosoma mansoni infection: randomised controlled trial. Lancet 2000; 355: 1320-5.
63. N'Goran EK, Utzinger J, Gnaka HN, Yapi A, N'Guessan NA, Kigbafori SD, Lengeler C, Chollet J, Xiao SH, Tanner M. Random- ized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections. Am J Trop Med Hyg 2003; 68: 24-32.
64. Keiser J, Utzinger J. Artemisinins and synthetic trioxolanes in the treatment of helminth infections. Curr Opin Infect Dis 2007; 20: 605-12.
65. Utzinger J, Tanner M, Keiser J. ACTs for schistosomiasis: do they act? Lancet Infect Dis 2010; 10: 579-81.
66. Sissoko MS, Dabo A, Traore H, Diallo M, Traore B, Konate D, Niare B, Diakite M, Kamate B, Traore A, Bathily A, Tapily A, Toure OB, Cauwenbergh S, Jansen HF, Doumbo OK. Efficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children. PLoS One 2009; 4: e6732.
67. Danso-Appiah A, Utzinger J, Liu J, Olliaro P. Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev 2008; CD000053.
68. Fortin A, Jansen FH. ACTs for the treatment of schistosomiasis. Lancet Infect Dis 2011; 11: 498.
69. Vennerstrom JL, Arbe-Barnes S, Brun R, Charman SA, Chiu FCK, Chollet J, Dong YX, Dorn A, Hunziker D, Matile H, McIntosh K, Padmanilayam M, Santo Tomas J, Scheurer C, Scorneaux B, Tang YQ, Urwyler H, Wittlin S, Charman WN. Identification of an antimalarial synthetic trioxolane drug development candidate. Nature 2004; 430: 900-4.
70. Boissier J, Cosledan F, Robert A, Meunier B. In vitro activities of trioxaquines against Schistosoma mansoni. Antimicrob Agents Chemother 2009; 53: 4903-6.
71. Xiao SH, Keiser J, Chollet J, Utzinger J, Dong Y, Vennerstrom JL, Tanner M. The in vitro and in vivo activities of synthetic trioxolanes on major human schistosome species. Antimicrob Agents Chemother 2007; 51: 1440-5.
72. Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, Charman WN, Chiu FC, Chollet J, Craft JC, Creek DJ, Dong Y, Matile H, Maurer M, Morizzi J, Nguyen T, Papastogiannidis P, Scheurer C, Shackleford DM, Sriraghavan K, Stingelin L, Tang Y, Urwyler H, Wang X, White KL, Wittlin S, Zhou L, Vennerstrom JL. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci USA 2011; 108: 4400-5.
73. Keiser J, Ingram K, Vargas M, Chollet J, Wang X, Dong Y, Vennerstrom JL. In vivo activity of aryl ozonides against Schistosoma species. Antimicrob Agents Chemother 2012; 56: 1090-2.
74. Meunier B. Hybrid molecules with a dual mode of action: dream or reality? Acc Chem Res 2008; 41: 69-77.
75. Cosledan F, Fraisse L, Pellet A, Guillou F, Mordmuller B, Kremsner PG, Moreno A, Mazier D, Maffrand JP, Meunier B. Selection of a trioxaquine as an antimalarial drug candidate. Proc Natl Acad Sci USA 2008; 105: 17579-84.
76. Pradines V, Portela J, Boissier J, Cosledan F, Meunier B, Robert A. Trioxaquine PA1259 alkylates heme in the blood-feeding parasite Schistosoma mansoni. Antimicrob Agents Chemother 2009; 55: 2403-5.
77. Schlagenhauf P, Adamcova M, Regep L, Schaerer MT, Rhein HG. The position of mefloquine as a 21st century malaria chemoprophylaxis. Malar J 2010; 9: 357.
78. Keiser J, Chollet J, Xiao SH, Mei JY, Jiao PY, Utzinger J, Tanner M. Mefloquine - an aminoalcohol with promising antischistosomal properties in mice. PLoS Negl Trop Dis 2009; 3: e350.
79. Manneck T, Braissant O, Ellis W, Keiser J. Schistosoma mansoni: antischistosomal activity of the four optical isomers and the two racemates of mefloquine on schistosomula and adult worms in vitro and in vivo. Exp Parasitol 2011; 127: 260-9.
80. Xiao SH, Chollet J, Utzinger J, Mei JY, Jiao PY, Keiser J, Tanner M. Effect of single-dose oral mefloquine on the morphology of adult Schistosoma japonicum in mice. Parasitol Res 2009; 105: 853-61.
81. Ingram K, Ellis W, Keiser J. Antischistosomal activities of mefloquine-related arylmethanols. Antimicrob Agents Chemother 2012; 56(6), 3207-15.
82. Keiser J, N'Guessan NA, Adoubryn KD, Silué KD, Vounatsou P, Hatz C, Utzinger J, N'Goran EK. Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin Infect Dis 2010; 50: 1205-13.
83. Aarnoudse AL, van Schaik RH, Dieleman J, Molokhia M, van Riemsdijk MM, Ligthelm RJ, Overbosch D, van der Heiden IP, Stricker BH. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther 2006; 80: 367-74.
84. Alisky JM, Chertkova EL, Iczkowski KA. Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis. Med Hypotheses 2006; 67: 1090-4.
85. Milatovic D, Jenkins JW, Hood JE, Yu Y, Rongzhu L, Aschner M. Mefloquine neurotoxicity is mediated by non-receptor tyrosine kinase. Neurotoxicology 2011; 32: 578-85.
86. Famin O, Ginsburg H. Differential effects of 4-aminoquinolinecontaining antimalarial drugs on hemoglobin digestion in Plasmodium falciparum-infected erythrocytes. Biochem Pharmacol 2002; 63: 393-8.
87. Manneck T, Haggenmüller Y, Keiser J. Morphological effects and tegumental alterations induced by mefloquine on schistosomula and adult flukes of Schistosoma mansoni. Parasitology 2010; 137: 85-98.
88. Manneck T, Keiser J, Müller J. Mefloquine interferes with glycolysis in schistosomula of Schistosoma mansoni via inhibition of enolase. Parasitology 2012; 139: 497-505.
89. Muregi FW, Kirira PG, Ishih A. Novel rational drug design strategies with potential to revolutionize malaria chemotherapy. Curr Med Chem 2011; 18: 113-43.
90. White NJ. Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 1999; 41: 301-8.
91. Keiser J, Manneck T, Vargas M. Interactions of mefloquine with praziquantel in the Schistosoma mansoni mouse model and in vitro. J Antimicrob Chemother 2011; 66: 1791-7.
92. Xiao SH, Mei JY, Jiao PY. Effect of mefloquine administered orally at single, multiple, or combined with artemether, artesunate, or praziquantel in treatment of mice infected with Schistosoma japonicum. Parasitol Res 2011; 108: 399-406.